Cholesterol emboli syndrome risk factors

Jump to navigation Jump to search


Cholesterol emboli syndrome Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cholesterol emboli syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cholesterol emboli syndrome risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cholesterol emboli syndrome risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cholesterol emboli syndrome risk factors

CDC on Cholesterol emboli syndrome risk factors

Cholesterol emboli syndrome risk factors in the news

Blogs on Cholesterol emboli syndrome risk factors

Directions to Hospitals Treating Cholesterol emboli syndrome

Risk calculators and risk factors for Cholesterol emboli syndrome risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]

Overview

The most potent risk factor in the development of cholesterol emboli syndrome is atherosclerosis. Other risk factors include cardiovascular interventions such as angiography and cardiovascular surgery, aortic aneurysm, diabetes mellitus, hypertension, dyslipidemia, smoking, aging, male sex, anticoagulants such as warfarin, thrombolytic therapy and higher serum CRP levels.

Risk Factors

References

  1. 1.0 1.1 Ozkok, Abdullah (2019). "

    Cholesterol-embolization syndrome: current perspectives

    ". Vascular Health and Risk Management. Volume 15: 209–220. doi:10.2147/VHRM.S175150. ISSN 1178-2048.
  2. Saklayen, Mohammad G.; Gupta, Satyendra; Suryaprasad, Agaram; Azmeh, Wayel; Saklayen, Mohammad G. (2016). "Incidence of Atheroembolic Renal Failure After Coronary Angiography". Angiology. 48 (7): 609–613. doi:10.1177/000331979704800707. ISSN 0003-3197.
  3. Fukumoto, Yoshihiro; Tsutsui, Hiroyuki; Tsuchihashi, Miyuki; Masumoto, Akihiro; Takeshita, Akira (2003). "The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study". Journal of the American College of Cardiology. 42 (2): 211–216. doi:10.1016/S0735-1097(03)00579-5. ISSN 0735-1097.
  4. Hyman, Bradley T.; Landas, Steve K.; Ashman, Robert F.; Schelper, Robert L.; Robinson, Robert A. (1987). "Warfarin-related purple toes syndrome and cholesterol microembolization". The American Journal of Medicine. 82 (6): 1233–1237. doi:10.1016/0002-9343(87)90231-2. ISSN 0002-9343.
  5. Varis, J.; Kuusniemi, K.; Jarvelainen, H. (2010). "Cholesterol microembolization syndrome: a complication of anticoagulant therapy". Canadian Medical Association Journal. 182 (9): 931–933. doi:10.1503/cmaj.090919. ISSN 0820-3946.
  6. Hitti, Wassim A; Wali, Ravinder K; Weiman, Edward J; Drachenberg, Cinthia; Briglia, Andrew (2008). "Cholesterol Embolization Syndrome Induced by Thrombolytic Therapy". American Journal of Cardiovascular Drugs. 8 (1): 27–34. doi:10.2165/00129784-200808010-00004. ISSN 1175-3277.

Template:WikiDoc Sources